Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Zealand Pharma

< Previous 1 2 Next >
Zealand Pharma completes registration of capital increase
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th
From Zealand Pharma
Via GlobeNewswire
U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma to highlight obesity pipeline at R&D Event on December 5
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma Announces Financial Results for the First Nine Months of 2023
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek
From Zealand Pharma
Via GlobeNewswire
Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
From Zealand Pharma
Via GlobeNewswire
SAVE THE DATE: Zealand Pharma to host Obesity R&D Event in London on December 5, 2023
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma to participate in upcoming healthcare conferences in September 2023
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma Announces Financial Results for the First Half of 2023
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma Hosts Conference Call on August 17 at 2pm CET (8am ET) to Present First Half 2023 Results
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions
From Zealand Pharma
Via GlobeNewswire
Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma Announces Financial Results for the First Quarter of 2023
From Zealand Pharma
Via GlobeNewswire
Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma Hosts Conference Call on May 11 at 2pm CET (8am ET) to Present First Quarter 2023 Results
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma to Participate in 22nd Annual Needham Virtual Healthcare Conference
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma announces completion of a directed issue and private placement of 6,578,948 million new ordinary shares raising gross proceeds of DKK 1.5 billion
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma announces directed issue and private placement of approximately 6.5 million new shares
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396
From Zealand Pharma
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.